Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer

(2016) Xiaoyong Fu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance

(2016) Molly Gale et al.   Oncotarget

PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer

(2016) Jennifer M. Spangle et al.   Cell Reports

MEL-18 loss mediates estrogen receptor–α downregulation and hormone independence

(2015) Jeong-Yeon Lee et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

(2015) Stephen R. D. Johnston   JNCI-Journal of the National Cancer Institute

DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression

(2015) Min-Hyung Cho et al.   Nature Communications

HOXB7 Is an ER  Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance

(2015) K. Jin et al.   Cancer Discovery

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

(2015) Stephen R. D. Johnston   JNCI-Journal of the National Cancer Institute

A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer

(2014) Ping Fan et al.   EUROPEAN JOURNAL OF CANCER

Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis

(2014) Lupeng Li et al.   Molecular Cancer

Retinoblastoma Binding Protein 2 (RBP2) Promotes HIF-1α–VEGF-Induced Angiogenesis of Non-Small Cell Lung Cancer via the Akt Pathway

(2014) Lei Qi et al.   PLoS One

Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis

(2014) Jian Cao et al.   Cell Reports

Histone Demethylase RBP2 Promotes Lung Tumorigenesis and Cancer Metastasis

(2013) Y.-C. Teng et al.   CANCER RESEARCH

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

(2013) John FR Robertson et al.   LANCET ONCOLOGY

RBP2 Induces Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

(2013) Shikun Wang et al.   PLoS One

Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

(2012) A Gallardo et al.   BRITISH JOURNAL OF CANCER

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

(2012) Caryn S. Ross-Innes et al.   NATURE

Maintenance of gene silencing by the coordinate action of the H3K9 methyltransferase G9a/KMT1C and the H3K4 demethylase Jarid1a/KDM5A

(2012) C.-P. Chaturvedi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer

(2011) Wilbert Zwart et al.   EMBO JOURNAL

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

(2011) Todd W. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1

(2011) W. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells

(2010) Nguyen Thi Thuy Phuong et al.   BREAST CANCER RESEARCH AND TREATMENT

Genetic Screen Identifies Insulin-like Growth Factor Binding Protein 5 as a Modulator of Tamoxifen Resistance in Breast Cancer

(2010) B. Y. Ahn et al.   CANCER RESEARCH

Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin

(2010) X. Huang et al.   CANCER RESEARCH

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Histone demethylase KDM5A is an integral part of the core Notch-RBP-J repressor complex

(2010) R. Liefke et al.   GENES & DEVELOPMENT

Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers

(2009) Lindsay A. Brown et al.   BREAST CANCER RESEARCH AND TREATMENT

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

(2009) Balazs Györffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase

(2009) Zheng Ge et al.   FASEB JOURNAL

Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor

(2009) K. R. Coser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-Repressive Complex 2

(2008) D. Pasini et al.   GENES & DEVELOPMENT

Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen

(2008) Antoni Hurtado et al.   NATURE

The ARID domain of the H3K4 demethylase RBP2 binds to a DNA CCGCCC motif

(2008) Shengjiang Tu et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY